## The testosterone paradox: Optimising outcomes for prostate cancer patients

Industry Session sponsored by ASTELLAS PHARMA EUROPE

**Friday 15 March**  
**16:15 - 17:45**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker(s)</th>
</tr>
</thead>
</table>
| 16:15 - 16:20 | Welcome and introduction  
F.J. Burgos Revilla, Madrid (ES) |                                                |
| 16:20 - 16:30 | Testosterone in the human body: Prostate cancer and testosterone  
F.J. Burgos Revilla, Madrid (ES) |                                                |
| 16:30 - 16:50 | Managing testosterone in the prostate cancer patient  
D.A. Pérez Fentes, Santiago de Compostela (ES) |                                                |
| 16:50 - 17:25 | Effects of androgen deprivation in men with prostate cancer: Gains from physical activity  
P.B. Østergren, Herlev (DK) |                                                |
| 17:25 - 17:40 | Panel discussion and audience Q&A  
**Panel:**  
F.J. Burgos Revilla, Madrid (ES)  
P.B. Østergren, Herlev (DK)  
D.A. Pérez Fentes, Santiago de Compostela (ES) |                                                |
| 17:40 - 17:45 | Summary and close |                                                |

This session is only accessible for persons authorized to prescribe and/or supply medicine (healthcare professionals)

Esta sesión está sólo permitida para profesionales sanitarios autorizados a prescribir o dispensar medicamentos
<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>16:15 - 16:20</td>
<td>Welcome and introduction</td>
<td>O. Traxer, Paris (FR)</td>
</tr>
<tr>
<td>16:20 - 16:35</td>
<td>NBI and PLASMA - The ideal surgical solution for NMIBC treatment</td>
<td>M. Babjuk, Prague (CZ)</td>
</tr>
<tr>
<td>16:35 - 16:50</td>
<td>iTind - Revolutionising the treatment of BPH?</td>
<td>F. Porpiglia, Turin (IT)</td>
</tr>
<tr>
<td>16:50 - 17:10</td>
<td>Developments in flexible ureteroscopy</td>
<td>O. Traxer, Paris (FR)</td>
</tr>
<tr>
<td>17:10 - 17:20</td>
<td>Advanced lithotripsy: Evolution of lithotripters</td>
<td>P.J.S. Osther, Fredericia (DK)</td>
</tr>
<tr>
<td>17:20 - 17:40</td>
<td>The role of 3D laparoscopy in a world of growing robotic surgery</td>
<td>J-U. Stolzenburg, Leipzig (DE)</td>
</tr>
<tr>
<td>17:40 - 17:45</td>
<td>Questions and closing remarks</td>
<td>O. Traxer, Paris (FR)</td>
</tr>
</tbody>
</table>
# Optimizing survival in metastatic prostate cancer

**Industry Session sponsored by SANOFI GENZYME**

**Friday 15 March**

**16:15 - 17:45**

**Location:** Green Area, Room 4

**Chair:** N. Mottet, Saint-Étienne (FR)

This session is only accessible for persons authorized to prescribe and/or supply medicine (healthcare professionals)

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Speaker/Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>16:15 - 16:20</td>
<td>Introduction</td>
<td>N. Mottet, Saint-Étienne (FR)</td>
</tr>
<tr>
<td>16:20 - 16:40</td>
<td>Understanding disease biology to guide treatment decisions</td>
<td>Y. Loriot, Villejuif (FR)</td>
</tr>
<tr>
<td>16:40 - 17:00</td>
<td>Metastatic prostate cancer: where are we in 2019?</td>
<td>G. Kramer, Vienna (AT)</td>
</tr>
<tr>
<td>17:00 - 17:20</td>
<td>Management of older men with metastatic prostate cancer in daily practice</td>
<td>A. Birtle, Preston (GB)</td>
</tr>
<tr>
<td>17:20 - 17:40</td>
<td>Updated EAU guidelines for the management of metastatic prostate cancer</td>
<td>N. Mottet, Saint-Étienne (FR)</td>
</tr>
<tr>
<td><strong>17:40 - 17:45</strong></td>
<td>Q&amp;A and closing remarks</td>
<td>N. Mottet, Saint-Étienne (FR)</td>
</tr>
</tbody>
</table>
Localized low-risk prostate cancer: Focal therapy with TOOKAD® - The new standard?
Industry Session sponsored by STEBA BIOTECH

Location: Green Area, Room 19
Presenters: A.R. Azzouzi, Angers (FR)  
V.G. Mirone, Naples (IT)  
F. Montorsi, Milan (IT)  
A. Scherz, Rehovot (IL)  
M. Wirth, Dresden (DE)

This session is only accessible for persons authorized to prescribe and/or supply medicine (healthcare professionals)

16:15 - 16:20 Welcome  
M. Wirth, Dresden (DE)

16:20 - 16:35 TOOKAD - Mechanism of Action  
A. Scherz, Rehovot (IL)

16:35 - 16:50 Technical Aspects and training of centers  
A.R. Azzouzi, Angers (FR)

16:50 - 17:05 TOOKAD® 4 year follow-up data  
F. Montorsi, Milan (IT)

17:05 - 17:20 Radical prostatectomy after TOOKAD®: Feasibility and early results  
V.G. Mirone, Naples (IT)

17:20 - 17:35 TOOKAD® and upgraded G6 – Promis study  
M. Wirth, Dresden (DE)

17:35 - 17:45 Q&A - Panel
Aims and objectives of this session
According to the current definition, BPH progression consists of symptoms worsening, prostate size increase, possible AUR and, eventually, need for surgery, which is seen as the terminus of the path. During the symposium the “hidden progression” of BPH/BPO will be discussed, whose consequences go far beyond, affecting not only the risk of surgery but also the risk of surgery failure.

Even after correctly performed procedures and in absence of complications many patients still complain with persistent/relapsing LUTS, report incomplete voiding, keep on assuming BPH drugs. This might be the consequence of a long lasting untreated obstruction leading to irreversible bladder damage. An early and effective non-invasive treatment of obstruction might be crucial not only to improve symptoms and QoL in the short period, but also to delay the progressive deterioration of bladder function in the long term, to consent a better surgical outcome later on and to positively impact on the after-the-surgery lifespan.

This session is only accessible for persons authorized to prescribe and/or supply medicine (healthcare professionals)
### Treating CRPC as a single disease

**Industry Session sponsored by ASTELLAS PHARMA EUROPE**

**Saturday 16 March**  
**18:00 - 19:30**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Speaker/Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>18:00 - 18:05</td>
<td>Welcome and introduction</td>
<td>N. Shore, Myrtle Beach (US)</td>
</tr>
<tr>
<td>18:05 - 18:20</td>
<td>Challenges in PSA interpretation across the disease spectrum</td>
<td>J. Mateo, Barcelona (ES)</td>
</tr>
<tr>
<td>18:20 - 18:35</td>
<td>News in bone health and imaging in CRPC</td>
<td>A.S. Merseburger, Lübeck (DE)</td>
</tr>
<tr>
<td>18:35 - 19:00</td>
<td>Expert overview of nmCRPC</td>
<td>N. Shore, Myrtle Beach (US)</td>
</tr>
<tr>
<td>19:00 - 19:15</td>
<td>The impact of metastases on patient lives</td>
<td>A. Alcaraz, Barcelona (ES)</td>
</tr>
<tr>
<td>19:15 - 19:25</td>
<td>Panel discussion and audience questions</td>
<td>N. Shore, Myrtle Beach (US)</td>
</tr>
<tr>
<td>19:25 - 19:30</td>
<td>Summary and close</td>
<td>N. Shore, Myrtle Beach (US)</td>
</tr>
</tbody>
</table>

This session is only accessible for persons authorized to prescribe and/or supply medicine (healthcare professionals)

Esta sesión está sólo permitida para profesionales sanitarios autorizados a prescribir o dispensar medicamentos
Urogenital cancer treatment at a glance: Past, present and future

Industry Session sponsored by IPSEN

Saturday 16 March
18:00 - 19:30

Location: Green Area, Room 3
Chair: L. Martínez Piñeiro, Madrid (ES)

This session is only accessible for persons authorized to prescribe and/or supply medicine (healthcare professionals)

18:00 - 18:30
Challenging paradigms in advanced prostate cancer: A new era
M.J. Ribal Caparros, Barcelona (ES)

18:30 - 19:00
The changing landscape in advanced Renal Cell Cancer management
M-O. Grimm, Jena (DE)

19:00 - 19:30
Blue light flexible cystoscopy – Improving the patient experience
Y. Lotan, Dallas (US)
Common problems in bladder cancer: Evidence based debates
Industry Session sponsored by MEDAC

Saturday 16 March
18:00 - 19:30

Location: Green Area, Room 4
Chair: A.M. Kamat, Houston (US)
Panel: J. Bjerggaard Jensen, Aarhus N (DK)
P. Black, Vancouver (CA)
M. Burger, Regensburg (DE)
H. Mostafid, Guildford (GB)

This session is only accessible for persons authorized to prescribe and/or supply medicine (healthcare professionals)

18:00 - 18:10
Introduction and case presentations
A.M. Kamat, Houston (US)

18:10 - 18:30
Case-based debate 1 Should all patients undergoing 1st time TURB receive immediate post-TURB chemotherapy instillation?
P. Black, Vancouver (CA)
H. Mostafid, Guildford (GB)

18:30 - 18:50
Case based debate 2 High risk bladder cancer (TaHG with CIS): Is BCG induction sufficient?
J. Bjerggaard Jensen, Aarhus N (DK)
M. Burger, Regensburg (DE)

18:50 - 19:10
Case based debate 3 A patient with high risk bladder cancer (T1HG on TURBT, repeat TUR negative) who cannot have radical cystectomy: Is BCG the best option?
H. Mostafid, Guildford (GB)
M. Burger, Regensburg (DE)

19:10 - 19:20
Common problems

19:10 - 19:15
Common Problem 1 Recurrent low grade bladder tumor recurs after BCG/Chemotherapy - now what?
P. Black, Vancouver (CA)

19:15 - 19:20
Common Problem 2 How to prevent and manage BCG side effects
J. Bjerggaard Jensen, Aarhus N (DK)

19:20 - 19:30
Discussion and Closing Remarks
A.M. Kamat, Houston (US)
Which drugs are the best for OAB? From patients' expectations to physicians' decision
Industry Session sponsored by PIERRE FABRE MÉDICAMENT

Saturday 16 March
18:00 - 19:30

Location: Green Area, Room 11
Chair: C.R. Chapple, Sheffield (GB)

This session is only accessible for persons authorized to prescribe and/or supply medicine (healthcare professionals)

18:00 - 18:05
Welcome and Introduction
C.R. Chapple, Sheffield (GB)

18:05 - 18:30
Expectations and concerns in OAB: Patients' perspective
A. Wagg, Edmonton (CA)
M. Oelke, Gronau (DE)

18:30 - 18:55
What do we learn from the Multi Criteria Decision Analysis Model?
I. Milsom, Gothenburg (SE)

18:55 - 19:20
What can physicians expect from treatments for their patients?
M. Oelke, Gronau (DE)
A. Wagg, Edmonton (CA)

19:20 - 19:30
Closing remarks
C.R. Chapple, Sheffield (GB)
<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>18:00 - 18:05</td>
<td><strong>Introduction</strong></td>
<td>K. Fizazi, Villejuif (FR)</td>
</tr>
<tr>
<td>18:05 - 18:35</td>
<td><strong>The role of emerging agents in the treatment of nmCRPC</strong></td>
<td>K. Fizazi, Villejuif (FR)</td>
</tr>
<tr>
<td>18:35 - 19:05</td>
<td><strong>The importance of quality of survival in the evolving nmCRPC landscape</strong></td>
<td>B. Tombal, Brussels (BE)</td>
</tr>
<tr>
<td>19:05 - 19:25</td>
<td><strong>Panel discussion and Q&amp;A</strong></td>
<td>K. Fizazi, Villejuif (FR)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>B. Tombal, Brussels (BE)</td>
</tr>
<tr>
<td>19:25 - 19:30</td>
<td><strong>Closing</strong></td>
<td>K. Fizazi, Villejuif (FR)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>B. Tombal, Brussels (BE)</td>
</tr>
</tbody>
</table>
**Leading change in NMIBC monitoring - Insights from successful implementation of Bladder EpiCheck in clinical routine**

Industry Workshop sponsored by NUCLEIX

**Saturday 16 March**

**18:00 - 19:30**

**Location:** Green Area, Room 19

**Chair:** J.A. Witjes, Nijmegen (NL)

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>18:00 - 18:05</td>
<td><strong>Introduction</strong>&lt;br&gt;J.A. Witjes, Nijmegen (NL)</td>
</tr>
<tr>
<td>18:05 - 18:25</td>
<td><strong>Bladder EpiCheck results - impact on my clinical practice</strong>&lt;br&gt;J.A. Witjes, Nijmegen (NL)</td>
</tr>
<tr>
<td>18:25 - 18:45</td>
<td><strong>Utilization of cystoscopy, cytology and Bladder EpiCheck – when best to use each one and why?</strong>&lt;br&gt;S. Lerner, Houston (US)</td>
</tr>
<tr>
<td>18:45 - 18:55</td>
<td><strong>Utilization of Bladder EpiCheck in high-risk population – experience from a large referral center</strong>&lt;br&gt;P.F. Bassi, Rome (IT)</td>
</tr>
<tr>
<td>18:55 - 19:05</td>
<td><strong>Adding Bladder EpiCheck to cytology to improve NMIBC detection – experience from a regional public hospital</strong>&lt;br&gt;C. D'Elia, Bolzano (IT)</td>
</tr>
<tr>
<td>19:05 - 19:15</td>
<td><strong>Bladder EpiCheck as a tool to reduce re-TURBT – pilot study results</strong>&lt;br&gt;R. Miano, Rome (IT)</td>
</tr>
<tr>
<td>19:15 - 19:25</td>
<td><strong>Bladder EpiCheck in upper tract tumors - feasibility study results</strong>&lt;br&gt;A. Breda, Barcelona (ES)</td>
</tr>
<tr>
<td>19:25 - 19:30</td>
<td><strong>Summary</strong>&lt;br&gt;J.A. Witjes, Nijmegen (NL)</td>
</tr>
</tbody>
</table>
UTI-quo vadis? New alternatives to treat uncomplicated urinary tract infections

Industry Session sponsored by BIONORICA SE

Saturday 16 March
18:00 - 19:30

Location: Green Area, Room 20
Chair: K. Naber, Straubing (DE)

Aims and objectives of this session
In recent years, we face a dramatic increase in antibiotic resistance. Results of the worldwide GPIU study show resistance rates between 8% and 62% for commonly used antibiotics. Despite the serious problem of antibiotic resistance, current guidelines still recommend the use of antibiotics for treatment of uncomplicated UTI due to proven effectiveness. But recent data also indicate that non-antibiotic, symptomatic treatment is sufficient, as shown in a recent high quality RCT comparing the herbal medicinal product Canephron® N to fosfomycin.

The speakers will highlight the problem of antibiotic resistance, discuss treatment options, and present novel data comparing symptomatic herbal treatment to standard antibiotic therapy.

This session is only accessible for persons authorized to prescribe and/or supply medicine (healthcare professionals)

18:00 - 18:05
Introduction
K. Naber, Straubing (DE)

18:05 - 18:25
Antibiotic resistance and appropriate empiric antibiotic therapy. Implications from GPIU studies
Z. Tandoğdu, Edinburgh (GB)

18:25 - 18:45
Impact of antibiotic resistance on management of patients with UTI/uUTI – Case reports from the clinic
B. Köves, Budapest (HU)

18:45 - 19:05
Treatment options of UTI/uUTI according to current European national and international guidelines
G. Bonkat, Basel (CH)

19:05 - 19:25
Presentation of a new double blind, randomized phytotherapeutic study in uUTI
F.M.E. Wagenlehner, Giessen (DE)

19:25 - 19:30
Discussion
Individualized care in the era of immuno-oncology: Focus on bladder and renal cancers

Aims and objectives of this session
Immune checkpoint inhibitors play a key role in medical management of select patients with urologic cancers. Using interactive case discussions, this session will focus on the rationale for targeting the immune checkpoint pathway in bladder and renal cancers; the role of biomarkers such as programmed death-ligand 1 (PD-L1) and tumor mutation burden (TMB) to guide the selection of appropriate first- and subsequent-line therapy; the use of immune-specific response criteria to monitor treatment response; and options for managing immune-related adverse events during treatment.

CME information
Siyem Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Siyem Learning designates this activity for 1.5 AMA PRA Category 1 credits™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

Learning objectives
• Evaluate the rationale for targeting immune checkpoint molecules in bladder and renal cancers
• Apply the latest clinical evidence to the selection and sequencing of immuno-oncology (IO) therapies in patients with bladder and renal cancers
• Select appropriate strategies to assess treatment response and mitigate adverse events during IO therapy

17:45 - 17:50 Welcome and introduction
R. Nair, London (GB)

17:50 - 18:15 Checkpoint inhibitors in urologic cancers: Where are we and where are we going?
M.C. Mir Maresma, Valencia (ES)
M. Kramer, Lübeck (DE)

18:15 - 18:40 Case 1: Patient with advanced renal cancer
M.C. Mir Maresma, Valencia (ES)

18:40 - 19:05 Case 2: Patient with newly diagnosed bladder cancer
M. Kramer, Lübeck (DE)

19:05 - 19:15 Q & A and closing remarks
R. Nair, London (GB)
## Real-time solutions in overactive bladder

*Industry Session sponsored by ASTELLAS PHARMA EUROPE*

### Location:
Green Area, Room 2

### Chair:
To be confirmed

### Aims and objectives of this session
During this symposium, we will explore ways to improve the success of overactive bladder treatment, focusing on a collaborative, patient-centric approach. We will discuss recent progress and current challenges in management, and consider how the latest data can be used to inform treatment decisions. We will also examine dialogue between patients and physicians and devise practical solutions for optimising communication.

This session is only accessible for persons authorized to prescribe and/or supply medicine (healthcare professionals)

Esta sesión está sólo permitida para profesionales sanitarios autorizados a prescribir o dispensar medicamentos

### Schedule

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Chair</th>
</tr>
</thead>
<tbody>
<tr>
<td>17:45 - 17:50</td>
<td>Welcome and introduction</td>
<td>To be confirmed</td>
</tr>
<tr>
<td>17:50 - 18:10</td>
<td>Sociolinguistics and OAB: Time for a better conversation</td>
<td>To be confirmed</td>
</tr>
<tr>
<td>18:10 - 18:25</td>
<td>Time to break adaptive behaviours in OAB</td>
<td>To be confirmed</td>
</tr>
<tr>
<td>18:25 - 18:45</td>
<td>Making the most of your consultation time: Selecting the right treatment for the right patient</td>
<td>To be confirmed</td>
</tr>
<tr>
<td>18:45 - 19:00</td>
<td>Out of sight is not out of mind: Improving persistence in OAB</td>
<td>To be confirmed</td>
</tr>
<tr>
<td>19:00 - 19:10</td>
<td>Audience questions</td>
<td></td>
</tr>
<tr>
<td>19:10 - 19:15</td>
<td>Closing remarks</td>
<td>To be confirmed</td>
</tr>
</tbody>
</table>
Is earlier better? Current questions on why, when, and how to treat non-metastatic castration-resistant prostate cancer

Industry Session sponsored by JANSSEN

Sunday 17 March 17:45 - 19:15

Location: Green Area, Room 3

Aims and objectives of this session
After attending this meeting, participants should be able to:
• Discuss the need for and the clinical benefits of earlier treatment in patients with castration-resistant prostate cancer (CRPC)
• Define the clinical impact of delaying metastases in prostate cancer
• Review the current clinical treatment options and management in non-metastatic castration-resistant prostate cancer (nmCRPC)

This programme is developed by the Scientific Committee: Eleni Efstathiou and Fred Saad

This session is only accessible for persons authorized to prescribe and/or supply medicine (healthcare professionals)

17:45 - 17:50
Introduction
F. Saad, Montréal (CA)

17:50 - 18:05
Is earlier treatment better? Lessons learned from mCRPC and mHSPC
M. Ramírez-Backhaus, Valencia (ES)

18:05 - 18:20
What is high-risk nmCRPC and how important is MFS?
B.A. Hadaschik, Essen (DE)

18:20 - 18:45
Why, when and how to treat nmCRPC? Taking a closer look at the results
F. Saad, Montréal (CA)

18:45 - 19:00
Where do we go from here? Sequencing, combining, and personalising care
E. Efstathiou, Houston (US)

19:00 - 19:15
Discussion and questions
Hexanic extract of Serenoa repens from lab to clinical practice: Claiming its position in the LUTS armamentarium
Industry Session sponsored by PIERRE FABRE MÉDICAMENT

Sunday 17 March 17:45 - 19:15
Location: Green Area, Room 11
Chair: A. De La Taille, Créteil (FR)

This session is only accessible for persons authorized to prescribe and/or supply medicine (healthcare professionals)

17:45 - 17:50 Welcome and introduction
A. De La Taille, Créteil (FR)

17:50 - 18:15 What makes HESr different from other plant extracts? New results from a metabolomics study.
F. Scaglione, Milan (IT)

18:15 - 18:40 Does HESr have a specific prostatic anti-inflammatory effect?
S. Gravas, Larissa (GR)

18:40 - 19:05 What do real life results tell us? The Qualiprostone study.
M. Gacci, Florence (IT)

19:05 - 19:15 Closing remarks
A. De La Taille, Créteil (FR)
Industry Session by GlaxoSmithKline

Sunday 17 March
17:45 - 19:15

Location: Green Area, Room 18
| Scientific Workshop on drug disease modelling in BPH: Discussion on the application of drug disease modelling related to dutasteride and its combination with tamsulosin |
|---|---|
| **Location:** | Green Area, Room 18 |
| **Sunday 17 March** | **17:45 - 19:15** |

Industry Workshop by GSK